Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?
作者信息
Wang Victoria E, Gainor Justin F
机构信息
Department of Medicine, University of California, San Francisco, San Francisco.
Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco.
出版信息
JAMA Oncol. 2024 Jan 1;10(1):52-53. doi: 10.1001/jamaoncol.2023.5004.
PMID:37991771
Abstract
摘要
相似文献
1
Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?奥希替尼用于非小细胞肺癌及罕见表皮生长因子受体（EGFR）突变患者——追逐独角兽？
JAMA Oncol. 2024 Jan 1;10(1):52-53. doi: 10.1001/jamaoncol.2023.5004.
2
Patients with uncommon EGFR mutations also benefit from first-line osimertinib.具有罕见表皮生长因子受体（EGFR）突变的患者也能从一线使用奥希替尼中获益。
Nat Rev Clin Oncol. 2024 Feb;21(2):84. doi: 10.1038/s41571-023-00847-x.
3
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.未经治 NSCLC 患者中常见 EGFR 突变的一线奥希替尼治疗：UNICORN 期 2 非随机临床试验。
JAMA Oncol. 2024 Jan 1;10(1):43-51. doi: 10.1001/jamaoncol.2023.5013.
4
Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC.简短报告：ⅢA期表皮生长因子受体（EGFR）突变型非小细胞肺癌（NSCLC）新辅助奥希替尼分子分析策略的评估
Clin Lung Cancer. 2024 Jan;25(1):e58-e61. doi: 10.1016/j.cllc.2023.08.012. Epub 2023 Aug 30.
5
Risk Factors Associated with Suboptimal Real-World Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Front-Line Recommended Therapy.表皮生长因子受体（EGFR）突变的非小细胞肺癌患者接受一线推荐治疗后，与欠佳的真实世界治疗结果相关的风险因素
Adv Ther. 2025 May 29. doi: 10.1007/s12325-025-03234-3.
6
Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.致信：奥希替尼治疗后疾病进展的表皮生长因子受体（EGFR）突变型晚期非小细胞肺癌（NSCLC）患者中，amivantamab联合化疗加或不加lazertinib：III期MARIPOSA-2研究的主要结果
Ann Oncol. 2024 Mar;35(3):327. doi: 10.1016/j.annonc.2023.11.007. Epub 2023 Dec 6.
7
Possible new mechanisms of primary drug resistance in NSCLC with EGFR mutation treated with Osimertinib.奥希替尼治疗的EGFR突变非小细胞肺癌原发性耐药的可能新机制。
IUBMB Life. 2025 Feb;77(2):e70002. doi: 10.1002/iub.70002.
8
Lazarus effect in a patient initially empirically treated with osimertinib for L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report.奥希替尼治疗 L858R 突变型非小细胞肺癌伴脑膜疾病患者的拉扎勒斯效应：病例报告
Oncotarget. 2024 Jan 16;15:27-30. doi: 10.18632/oncotarget.28550.
9
Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC.化疗与奥希替尼联合不应作为所有晚期表皮生长因子受体阳性非小细胞肺癌的一线治疗方案。
J Thorac Oncol. 2024 Mar;19(3):376-379. doi: 10.1016/j.jtho.2023.12.007.
10
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.辅助性表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）用于治疗已切除的Ⅰ至Ⅲ期非小细胞肺癌且伴有EGFR突变的患者。
Cochrane Database Syst Rev. 2025 May 27;5(5):CD015140. doi: 10.1002/14651858.CD015140.pub2.
引用本文的文献
1
Evolving Precision First-Line Systemic Treatment for Patients with Unresectable Non-Small Cell Lung Cancer.不可切除非小细胞肺癌患者不断发展的精准一线全身治疗
Cancers (Basel). 2024 Jun 26;16(13):2350. doi: 10.3390/cancers16132350.
Zotero 插件